A review of the clinical uses of ximelagatran in thrombosis syndromes

Journal of Thrombosis and Thrombolysis

Volumn 16, Issue 3, 2003, Pages 175-188

  Bergsrud, Elizabeth A ^a   Gandhi, Pritesh J ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Direct thrombin inhibitors; Melagatran; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; DIAZEPAM; DICLOFENAC; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NIFEDIPINE; PLACEBO; RECOMBINANT HIRUDIN; THROMBIN; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; HEART ATRIUM FIBRILLATION; HUMAN; INTRAOCULAR HEMORRHAGE; KIDNEY FAILURE; LIVER DYSFUNCTION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; REVIEW; STROKE; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION; DRUG INTERACTIONS; HUMANS; MYOCARDIAL INFARCTION; THROMBOSIS;

EID: 4344683927     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:THRO.0000024056.84909.b0     Document Type: Review

References (41)

1. Hyers TM. Management of venous thromboembolism. Arch Intern Med 2003 163:759-768.
2. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998;79:110-118.
3. Hauptmann J, Sturzebecher J. Synthetic inhibitors of thrombin and factor Xa: From bench to bedside. Thromb Res 1999;93:203-241.
4. FitzGerald GA. The human pharmacology of thrombin inhibition. Coronary Artery Disease 1996;7:911-918.
5. Prasa D, Svendsen L, Sturzebecher J. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thromb Haemost 1997;77:498-503.
6. Beguin S, Welzel D, Al Dieri R, Hemker HC. Conjectures and refutations on the mode of actions of heparins. Haemostasis 1999;29:170-178.
7. Sarich TC, Eriksson UG, Mattsson C, et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002;87:300-305.
8. Sarich TC, Wolzt M, Eriksson UG, et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 2003;41:557-564.
9. Gustafsson D, Nystrom J-E, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001 ;101:171-181.
10. Clement B, Lopian K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos 2003;31:645-651.
11. Wahlander K, Lapidus L, Olsson C-G, et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 2002;107:93-99.
12. Eriksson BI, Arfwidsson A-C, Frison L, et al. A doseranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. Thromb Haemost 2002;87:231-237.
13. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003;59:35-43.
14. Eriksson UG, Bredberg U, Hoffmann K-J, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003;31:294-305.
15. Wolzt M, Wollbratt M, Svensson M, Wahlander K, Grind M, Eriksson UG. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur J Clin Pharmacol 2003;59:537-543.
16. Eriksson UG, Frison L, Gustafsson D, Mandema J, Karlsson MO, Eriksson B. Pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor H 376/95, in orthopedic surgery patients treated to prevent deep vein thrombosis and pulmonary embolism. Blood 2000 96/11:4087 (Abstract).
17. Eriksson H, Eriksson UG, Frison L, et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999;81:358-363.
18. Wahlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson U. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:755-764.
19. Johansson LC, Eriksson UG, Frison L, Fager G. Pharmocokinetics of H376/95 in young and elderly subjects. Blood 2000;96/11:239 (Abstract).
20. Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003 42:381-392.
21. Eriksson U, Johansson S, Attman PO, et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacokinet 2003 42:743-753.
22. Sarich TC, Teng R, Peters GR, et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 2003 42:485-492.
23. Johansson LC, Andersson M, Fager G, Gustafsson D, Eriksson UG. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 2003;42:475-484.
24. Mattsson C, Menschiek-Lundin A, Wahlander K, Lindahl TL. Effects of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thromb Haemost 2001;86:611-615.
25. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: A phase 2 dose-finding study. Arch Intern Med 2001;161:2215-2221.
26. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO II randomized trial. Lancet 2002;360:1441-1447.
27. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO III study. Thromb Haemost 2003;89:288-296.
28. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann Intern Med 2002;137:648-655.
29. Owen OG. The express study: Preliminary results. Int J Clin Pract 2003 57:57-59.
30. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-1712.
31. Colwell CW, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, doubleblind study. J Thrombo Haemost 2003;1:2119-2130.
32. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thrombo Haemost 2003;1:41-47.
33. Schulman S, Wahlander K, Lundstrom T, Billing-Clason S, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-1721.
34. Wahlander K, Lapidus L, Olsson CG, Thuresson A, Eriksson UG, Eriksson H. THRIVE IV: An open-label, pilot study of the treatment of pulmonary embolism with the oral direct thrombin inhibitor ximelagatran (Abstract). American Society of Hematology 43rd Annual Meeting. Orlando, FL. December 2001 (#1130).
35. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II. J Am Coll Cardiol 2003;41:1445-1451.
36. Halperin JL. Sportif III: A long-term randomized trial comparing ximelagatran with warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. American College of Cardiology 52nd Annual Scientific Session Chicago, Illinois. April 2003 (Session 421).
37. Halperin, JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003 146:431-438.
38. Palle P. A two-year follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Neurology 2002;58[(7)Suppl 3]:A477.
39. Wallentin L, Wilcox RG, Weaver WG, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomized controlled trial. Lancet 2003;362:789-797.
40. Fager G, Cullberg M, Eriksson-Lepkowska M, Frison L, Eriksson UG. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eur J Clin Pharmacol 2003;59:283-289.
41. Bredberg E, Andersson T, Frison L, et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome p450-mediated drug-drug interactions. Clin Pharmacokinet 2003;42:765-777.